Most importantly, SLA2 expression may affect the immune microenvironment and then indirectly affects the prognosis of HNSCC and serves as a predictor of ICB therapies and chemotherapeutics.However, the limitation of this study is that a large number of samples were needed to verify our results, and more clinical samples will be collected to enrich the data in the future. The gene discussed is SLA2; the disease is head and neck squamous cell carcinoma.